InnoCare and KeyMed jointly announce license agreement with Prolium for CD20xCD3 bispecific antibody ICP-B02 By Investing.com
BEIJING–( BUSINESS WIRE )–InnoCare Pharma (HKEX: 09969 ; SSE (LON: ): 688428 ) and KeyMed Biosciences (HKEX: 02162 ) today announced that the two companies, together with their joint venture, have jointly entered into an exclusive license agreement with Prolium Bioscience (Prolium) for the development and commercialization of ICP-B02 (CM355), CD20xCD3 bispecific antibody.
ICP-B02 binds to CD20 on tumor cells and CD3 on T cells, redirects and activates T cells to eradicate tumor cells via T-cell directed cell cytotoxicity (TDCC), which has shown strong potential in oncology and non-oncology fields.
Under the terms of the agreement, Prolium will have the exclusive right to develop, register, manufacture and commercialize ICP-B02 in the non-oncology field globally and in the oncology field in the former Asia regions.
InnoCare and KeyMed will receive total payments of up to $520 million, including upfront and short-term payments and other payments contingent on the achievement of certain clinical, regulatory and commercial milestones, as well as a minority equity interest in Prolium. InnoCare and KeyMed are also eligible to receive tiered royalties on future net sales of any product resulting from the collaboration.
Prolium is a Delaware company funded and backed by RTW Investments, LP, a New York-based global full-cycle investment firm focused on identifying transformative and disruptive innovations in the biopharmaceutical and medical technology sectors.
About ICP-B02 (CM355)
ICP-B02 is a CD20×CD3 bispecific antibody jointly developed by InnoCare and KeyMed. A phase I/II clinical trial is ongoing in China to evaluate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of ICP-B02 in relapsed/refractory non-Hodgkin’s lymphoma (NHL). The study showed promising early results with both intravenous (IV) and subcutaneous (SC) formulations, particularly in patients with follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). Based on the encouraging results of single agent ICP-B02, a dose-expansion study of ICP-B02 in combination with other immunochemotherapy is planned to target earlier lines of treatment in NHL patients. IND for combination therapies has been approved.
About InnoCare
InnoCare is a commercial biopharmaceutical company dedicated to the discovery, development and commercialization of first-in-class and/or best-in-class medicines for the treatment of cancer and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong and the United States.
About Keymed Biosciences
Keymed Biosciences Inc. (HKEX: 02162) focuses on urgent unmet clinical needs and is committed to providing high-quality, affordable, innovative therapies for patients in China and abroad. Keymed was founded by medical and scientific experts who have extensive experience in the transformation of scientific and technological achievements into commercialization in the country and abroad.
InnoCare Forward-Looking Statements
This report contains disclosure of certain forward-looking statements. Except for statements of fact, all other statements may be considered forward-looking statements, that is, about our or our management’s intentions, plans, beliefs or expectations that will or may occur in the future. Such statements are assumptions and estimates of our management based on its experience and knowledge of historical trends, current conditions, expected future developments and other related factors. This forward-looking statement does not guarantee future results, and actual results, developments and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a number of risks and uncertainties, which may affect our short-term and long-term results.
See the original version on businesswire.com: https://www.businesswire.com/news/home/20250120534760/en/
KeyMed
The media
Jin Zhao
86+28-88610620
pr@keymedbio.com
Investors
86+28-88610620
ir@keymedbio.com
InnoCare
The media
Chunhua Lu
86+10-66609879
chunhua.lu@innocarepharma.com
Investors
86+10-66609999
ir@Innocarepharma.com
Source: InnoCare Pharma
